Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum toxin B - Supernus Pharmaceuticals

Drug Profile

Botulinum toxin B - Supernus Pharmaceuticals

Alternative Names: AN 072; BoNT/B; BotB; Botulinum toxin type B; E 2014; Myobloc; NerBloc; Neurobloc; RimabotulinumtoxinB

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Solstice Neurosciences
  • Developer Eisai Co Ltd; Solstice Neurosciences; Supernus Pharmaceuticals; US WorldMeds
  • Class Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dystonia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Sialorrhoea; Torticollis
  • Phase II/III Muscle spasticity

Most Recent Events

  • 16 Nov 2021 Phase-II/III clinical trials in Muscle spasticity (In adults, In the elderly) in Czech Republic (IM) (NCT04815967)
  • 16 Nov 2021 Supernus Pharmaceuticals in collaboration with Solstice Neurosciences initiates enrolment in a phase II/III trial in Muscle spasticity (In adults, In the elderly) in USA (IM, Injection) (NCT04815967)
  • 27 Oct 2021 Supernus Pharmaceuticals in collaboration with Solstice Neurosciences plans a phase III trial for Sialorrhea(In children, In adolescents) in November 2021 (NCT05097079)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top